In addition, the expression of three stemness markers of pancreatic cancer including CD133, nestin and Lgr5 was also up-regulated suggesting GEM treatment may stimulate the stem-like properties of cancer cells and enrich a population of cancer stem cells (CSCs) with high drug resistance. This evidence concerns the gene NES and familial pancreatic carcinoma.